TMC Life Sciences redesignates Dr Chan Boon Kheng as ED

-A +A

KUALA LUMPUR (March 24): TMC Life Sciences Bhd has redesignated its non-executive director Dr Chan Boon Kheng as the company's executive director.  

Dr Chan, a Singaporean, has been a non independent non-executive director of TMC Life Sciences (fundamental: 2.5; valuation: 0.7) since January 12, 2011.

According to its filing to Bursa Malaysia, the 47-year-old doctor was an advisor and interim group chief executive officer (CEO) of Pantai Holdings Bhd (Pantai) between 2007 and 2010.
"He also served as an advisor to various healthcare companies in Malaysia, including the Mudabala Development Company based in Abu Dhabi and was the CEO and general manager of East Shore Hospital in Singapore under Parkway Healthcare, prior to joining Pantai," it added.  

The filing said Dr Chan is also the chairman of Innoheart, a pre-clinical Contract Research Organisation based in Singapore.  

“He is currently a director of healthcare consultancy companies whose activities ranges from transition management, process improvement, performance management and commercialising bioscience and technology applications,” it said.  

TMC Life Sciences closed half a sen or 0.77% at 64.5 sen, giving it a market capitalisation of RM779.69 million.

(Note: The Edge Research's fundamental score reflects a company’s profitability and balance sheet strength, calculated based on historical numbers. The valuation score determines if a stock is attractively valued or not, also based on historical numbers. A score of 3 suggests strong fundamentals and attractive valuations.)